Literature DB >> 14688687

Improved early outcome for end-stage dilated cardiomyopathy in children.

Anne-Marie McMahon1, Carin van Doorn, Michael Burch, Pauline Whitmore, Sophie Neligan, Philip Rees, Rosemary Radley-Smith, Allan Goldman, Katherine Brown, Gordon Cohen, Victor Tsang, Martin Elliott, Marc R de Leval.   

Abstract

OBJECTIVE: To review the impact of management changes on the early outcomes of end-stage dilated cardiomyopathy in children.
METHODS: We conducted a retrospective study of all consecutive children with end-stage dilated cardiomyopathy who received hospital treatment since 1992. Over the past 3 years the following management changes were made: (1) more aggressive use of mechanical cardiac assistance; (2) high priority listing for transplantation; and (3) ABO incompatible transplants for infants. Outcomes for 46 patients admitted between 1992 and 1999 (group I) were compared with 53 patients between 2000 and March 2003 (group II).
RESULTS: In group I, 12 (26%) patients received mechanical support with recovery in 3 and transplantation in 5 (1 died). In group II, 19 (36%) patients received extracorporeal membrane oxygenation, with recovery in 5 and transplantation in 12 (all survived). The use of mechanical assistance was associated with high morbidity related to bleeding, end-organ failure, and long-term mechanical ventilation. Five patients in group II received ABO incompatible transplants and all survived. There have been no episodes of rejection or need for increased immunosuppressive therapy. Hospital mortality has been significantly reduced (group I, 37% vs group II, 11%; P <.05).
CONCLUSIONS: Recent refinements in the management of end-stage dilated cardiomyopathy in children have significantly reduced early mortality. Identification of markers of early myocardial recovery and development of mechanical devices for longer term and more physiologic support are essential to achieve further improvements in outcome.

Entities:  

Mesh:

Year:  2003        PMID: 14688687     DOI: 10.1016/j.jtcvs.2003.07.029

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Immune suppressive treatment in paediatric myocarditis: still awaiting the evidence.

Authors:  M Burch
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

2.  A novel system of assessing myocardial recovery during left ventricular support: report of a case.

Authors:  Takaya Hoashi; Goro Matsumiya; Yasushi Sakata; Shigetoyo Kogaki; Yoshiki Sawa
Journal:  Surg Today       Date:  2008-02-01       Impact factor: 2.549

3.  Early predictors of survival to and after heart transplantation in children with dilated cardiomyopathy.

Authors:  Biagio A Pietra; Paul F Kantor; Heather L Bartlett; Clifford Chin; Charles E Canter; Ranae L Larsen; R Erik Edens; Steven D Colan; Jeffrey A Towbin; Steven E Lipshultz; James K Kirklin; David C Naftel; Daphne T Hsu
Journal:  Circulation       Date:  2012-07-16       Impact factor: 29.690

4.  Survival Without Cardiac Transplantation Among Children With Dilated Cardiomyopathy.

Authors:  Rakesh K Singh; Charles E Canter; Ling Shi; Steven D Colan; Debra A Dodd; Melanie D Everitt; Daphne T Hsu; John L Jefferies; Paul F Kantor; Elfriede Pahl; Joseph W Rossano; Jeffrey A Towbin; James D Wilkinson; Steven E Lipshultz
Journal:  J Am Coll Cardiol       Date:  2017-11-28       Impact factor: 24.094

5.  Clinical experience with Berlin Heart Excor in pediatric patients in Argentina: 1373 days of cardiac support.

Authors:  Guillermo E Moreno; Alberto Charroqui; María L Pilán; Ricardo H Magliola; Mariela P Krynski; María Althabe; Luis M Landry; Gabriela Sciuccati; Alejandra Villa; Horacio Vogelfang
Journal:  Pediatr Cardiol       Date:  2011-03-20       Impact factor: 1.655

6.  Idiopathic dilated cardiomyopathy in children; Natural history and predictors of prognosis.

Authors:  Inas Abdullsattar Saad
Journal:  Libyan J Med       Date:  2007-09-01       Impact factor: 1.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.